Recommendations for drug dosing in patients with chronic liver disease;Recomendaciones para la dosificación de medicamentos en pacientes con insuficiencia hepática crónica

Revista Espanola de Enfermedades Digestivas

Volumn 104, Issue 4, 2012, Pages 165-184

  Párraga, Leonor Periáñez ^a   Martínez López, Iciar ^a   Bosch, Pere Ventayol ^a   Latorre, Francesc Puigventós ^a   Sánchez, Olga Delgado ^a  

^a HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

Author keywords

Dose response relationship; Hepatic impairment; Liver disease; Liver dysfunction; Prescription drugs

Indexed keywords

PRESCRIPTION DRUG;

CHRONIC LIVER DISEASE; DOSE CALCULATION; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG MONITORING; LIVER DYSFUNCTION; REVIEW;

EID: 84860337652     PISSN: 11300108     EISSN: None     Source Type: Journal    
DOI: 10.4321/s1130-01082012000400002     Document Type: Review

References (27)

1. Delcò F, Tchambaz L, Schlienger R, Drewe J, Krahenbuhl S. Dose adjustment in patients with liver disease. Drug Saf 2005;28:529-45.
2. Child CG, Turcotte JG. Surgery and portal hypertension. In: Child CG, editor. The Liver and Portal Hypertension. Philadelphia: Saunders; 1964. p. 50.
3. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-9.
4. Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003;124:91-6.
5. Cholongitas E, Marelli L, Shusang V, Senzolo M, Rolles K, Patch D, et al. A systematic review of the performance of the model for endstage liver disease (MELD) in the setting of liver transplantation. Liver Transpl 2006;12:1049-61.
6. Guidance for industry: pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing and labelling. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research. FDA, 2003. Disponible en http://www.fda.gov/cber/gdlns/imphep.pdf (fecha última consulta 15 de Abril de 2011).
7. Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with impaired hepatic function. Committee for medicinal products for human use. EMA (CPMP/EWP/2339/02), 2005. Disponible en http://www.emea.europa.eu/pdfs/human/ewp/23390 (fecha última consulta 15 de Abril de 2011).
8. Stuart M, Kouimtzi M, Hill S, editors. WHO model formulary 2008. Geneva: WHO; 2008. Disponible en: http://www.who.int/selection_medicines/list/WMF2008.pdf (fecha última consulta 15 de Abril de 2011).
9. Drug Evaluation Monograph. En: Drugdex® Information System. Micromedex Inc. Engleewood: Staff; 2011. (fecha última consulta 15 de Abril de 2011).
10. Do Pazo F, Calvo C, Puigventós F, Ventayol P, Periañez L. Developing a search engine for pharmacoterapeutic information that is not published in biomedical journals. Farm Hosp 2011;35:254.e1-254.e5.
11. Huet PM, Villeneuve JP. Determinants of drug disposition in patients with cirrhosis. Hepatology 1983;3:913-8.
12. Krähenbühl S, Reichen J. Pharmacokinetics and pharmacodynamics in cirrhosis. Medicine 2002;30:24-7.
13. Westphal JF, Brogard JM. Drug administration in chronic liver disease. Drug Saf 1997;17:47-73.
14. Azanza JR, García E, Sádaba B, Manubens A. Uso de antimicrobianos en pacientes con insuficiencia renal o hepática. Enferm Infecc Microbiol Clin 2009;27:593-9.
15. Blaschke T.F. Effect of liver disease on dose optimization. International Congress Series 2001;1220:247-58.
16. Schlatter C, Egger SS, Tchambaz L, Krahenbuhl S. Pharmacokinetic changes of psychotropic drugs in patients with liver disease: implications for dose adaptation. Drug Saf 2009;32:561-78.
17. Pirmohamed M. Prescribing in liver disease. Medicine 2007;35:31-4.
18. Sloss A, Kluber P. Prescribing in liver disease. Aust Prescrib 2009;32:32-5.
19. Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol 2008;64:1147-61.
20. Shapiro J. "Hepatic dysfunction and drug dosing: The ABCs of the Child-Pugh Score". Drug & Therapy bulletin 2005;19:1-3.
21. Kim JW, Hattori A, Phongsamran PV. Drug-induced liver disease. Crit Care Nurs Clin North Am 2010;22:323-34.
22. Drug use in liver impairment. Drug information service. Canterbury District Health Board. October 2003. http://www.druginformation.co.nz/Bulletins/DrugsLiverDisease.pdf (fecha última consulta 15 de Abril de 2011).
23. Klotz U. Antiarrhythmics: elimination and dosage considerations in hepatic impairment. Clin Pharmacokinet 2007;46:985-96.
24. Spray JW, Willett K, Chase D, Sindelar R, Connelly S. Dosage adjustment for hepatic dysfunction based on Child-Pugh scores. Am J Health Syst Pharm 2007;64:690,692-3.
25. Vidal L, Shavit M, Fraser A, Paul M, Leibovici L. Systematic comparison of four sources of drug information regarding adjustment of dose for renal function. BMJ 2005;331:263.
26. Lozano-Lanagrán M, Robles M, Lucena MI, Andrade RJ. Hepatotoxicity in 2011 advancing resolutely. Rev Esp Enferm Dig 2011;103:472-9.
27. Centro de Información on-line de Medicamentos de la Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Ministerio de Sanidad, política social e igualdad. Acceso a fichas técnicas del medicamento aprobadas por la agencia española y por la Agencia Europea de Medicamentos (EMA). Disponibles en http://www.agemed.esy http://www.ema.europa.eu (fecha última consulta 15 de Abril de 2011).